Clinical trials and drug discovery
16 Kalunian KC, Furie R, Morand EF, et al . A Randomized, Placebo- Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis Rheumatol 2023;75:253–65. 17 Mathian A, Mouries-Martin S, Dorgham K, et al . Ultrasensitive serum interferon. Ann Rheum Dis 2019;78:1669–76. 18 Rodríguez-Carrio J, Burska A, Conaghan PG, et al . Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. RMD Open 2023;9:e002864.
19 He J, Li Z. Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. Rheumatology (Oxford ) 2023;62:i22–9. 20 Rubin B, Chen Y, Worley K, et al . Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real- World Descriptive Study. Rheumatol Ther 2024;11:947–62. 21 DerSarkissian M, Chen Y, Rabideau B, et al . Belimumab-treated patients with systemic lupus erythematosus without prior immunosuppressant use have more favorable clinical outcomes than those with prior use of an immunosuppressant. Arthritis Rheumatol 2024;76.
13
Doria A, et al . Lupus Science & Medicine 2026; 13 :e001891. doi:10.1136/lupus-2025-001891
Powered by FlippingBook